Drug intelligence / Profile preview

ReyaGel

Development stage: Unknown
Lead developer: FetTech
Administration: Topical

Overview

ReyaGel is an FDA-cleared liquid extracellular matrix (ECM) product developed by FetTech, LLC, utilizing their proprietary Multi-Tissue Platform (MTP) technology. It is composed of porcine spleen and lung-derived ECM, containing structural proteins like collagen and elastin along with various growth factors, formulated in a saline gel. ReyaGel is designed to support the body's natural regenerative healing processes by providing a biological scaffold that reduces inflammation, minimizes scarring, and enhances tissue recovery. It received 510(k) clearance in 2024 for the management of partial and full-thickness wounds and is also utilized in aesthetic applications, including post-procedural skin recovery (e.g., after CO2 laser or microneedling) and hair restoration.

Brand names: ReyaGel

Beyond the preview

Go deeper on ReyaGel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ReyaGel.

Explore the full profile